Directory · JP
Pharmaceutical Manufacturing in Japan
A register of firms and the professionals working at them in the Pharmaceutical Manufacturing sector based in Japan. Browse the public index, then filter or export on Kipplo.
Companies
255 on file
Astellas Pharma
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page:
10001+ staff
Recordati Rare Diseases
At Recordati Rare Diseases, we focus on the few - those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions. Social Media Guidelines:
201 to 500 staff
Chugai Pharmaceutical Co., Ltd
Chugai Pharmaceutical Co, Ltd, headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at Read our Social Media Policy:
5001 to 10000 staff
Shionogi & Co., Ltd
Philosophy The purpose of the Shionogi Group's corporate activities is, as expressed in the opening of its Company Policy, to "supply the best possible medicine to protect the health and wellbeing of the patients we serve." This eternal and unwavering corporate philosophy is a statement of our vision and value to society. To achieve and live by the Company Policy, we have formulated Action Guidelines, which all Shionogi employees share and embrace as norms for daily activities. Through activities based on the Company Policy and the Action Guidelines, Shionogi will continue to contribute to patients, physicians and other healthcare providers, shareholders and investors, and furthermore to society as a whole.
1001 to 5000 staff
Synowledge Llc
Synowledge is a global life sciences solutions company providing drug safety, regulatory affairs and relevant IT services to diverse pharmaceutical, biotechnology and medical devices companies. We provide industry thought leadership and competence in technology to innovate, optimize and maintain their drug safety applications, business processes and other critical IT applications. Our significant global presence, expertise and market-leading technologies assure reliable partnerships and high performance solutions to each of our clientele.
501 to 1000 staff
Towa Pharmaceutical
Founded in Osaka in 1951, for over 70 years we have been dedicated to research, develop, manufacture, and distribute generic medicines to fulfill our Ikigai: Contribute to people’s health and generate genuine smiles. Towa is listed on the Tokyo Stock Exchange and is one of Japan’s main leading companies in its sector. In the current super-aged society, we make continuous efforts for stable supplies of generics that can help reduce users’ medical payments and counter increasing social security and medical costs while maintaining the quality of medical services. In addition to promoting stable supply, quality assurance, and information provision about generics, we focus on research and development of innovative initiatives to make our products easier to take and handle. To enter new markets, we also promote the construction of a structure that can provide Towa group’s added-value formulations to patients around the world through our overseas companies.
1001 to 5000 staff
Eisai Co., Ltd
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.
1001 to 5000 staff
Pht International, Inc
PHT International is a Contract Research, Development and Manufacturing Organization (CRDMO) providing innovative solutions for worldwide pharmaceutical companies. Founded in 1993, PHT builds partnerships with leading brands through a commitment to integrity, solving problems and lasting relationships. Our operations has been frequently inspected by the FDA and customer. PHT has established an excellent safety, quality, and compliance track record in the global life sciences industry. PHT strives to be one of the leading CDMO companies within the next 5 years.
201 to 500 staff
Otsuka Pharmaceutical Co., Ltd
2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535, Japan
5001 to 10000 staff
Dishman Carbogen Amcis Ltd
Dishman is a global, dynamic group of companies offering a continuum of services to the pharmaceutical industry. We are a global outsourcing partner for pharmaceutical companies, offering a portfolio of products and development, scale-up and manufacturing services. The Dishman Group continually invests in the pharmaceutical industry, ensuring Dishman’s businesses can provide pharmaceutical customers with high-value, high-quality products and services today and in the future. Our focus is to add value to the global pharmaceutical industry by serving as a reliable partner. Our business is successful only when our customers are successful.
1001 to 5000 staff
Agc Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S, Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. Visit to learn more.
1001 to 5000 staff
Kyowa Kirin Co., Ltd
Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by a severe or rare disease. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International.
5001 to 10000 staff
Metagen Therapeutics, Inc
Metagen Therapeutics, Inc. is a drug discovery and development company that leverages the power of gut microbiome design cultivated in Metabologenomics, Inc. We are eager for partnerships in pharmaceutical, healthcare, functional food, and academia that envisions creating future businesses with one of the best microbiome scientist teams. For inquiries, please contact contact@metagentx.com
11 to 50 staff
Amgen Astellas Biopharma
201310 201320204149 Amgen has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K.(AABP), a joint venture between Amgen and Astellas established in 2013. AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K, has enabled Amgen to build a strong presence in Japan as it advances treatments for serious illnesses
501 to 1000 staff
Aska Pharmaceutical Co., Ltd
ASKA Pharmaceutical Co, Ltd. is a leading company in the field of Thyroid disease by through supplying a variety of medicines. Furthermore, we utilize our hormonal technology, aim to contribute all patients for obstetrics and gynecology area.
501 to 1000 staff
Otsuka Holdings Co., Ltd
In keeping with the corporate philosophy “Otsuka-people creating new products for better health worldwide” and the Otsuka values of Ryukan-godo (by sweat we recognize the way), Jissho (actualization) and Sozosei (creativity), we strive to do what only Otsuka can do. The Otsuka group supports the lives of people worldwide through a wide range of innovative and creative products including pharmaceuticals, functional beverages, and functional foods. “Otsuka-people creating new products for better health worldwide”3
51 to 200 staff
Spera Pharma, Inc
SPERA PHARMA (SPERA) was spun out from Takeda Pharmaceuticals and became a wholly owned subsidiary of Bushu Pharmaceuticals on July 1, 2017 in Osaka, Japan. On March 2, 2020, Iwaki & Co, Ltd acquired SPERA from Bushu. The IWAKI Group transitioned to a holding company structure under the new name “Astena Group” on June 1, 2021. SPERA has about 250 employees including researchers and technical specialists in the areas of process chemistry, formulation, and analysis, whose prior work with Takeda gave them broad exposure to all aspects of pharmaceutical R&D, manufacturing, and life cycle management across myriad pharmaceutical products and therapeutic areas. They are engaged in contract R&D and manufacturing of pharmaceuticals for the pharmaceutical and biotech industry. SPERA provides a wide offering of services as a CDMO to meet its customers’ needs across the CMC spectrum, including API and Drug Product process development and cGMP manufacturing, analytical method development, technology transfer, and regulatory filings. SPERA works with its clients on pharmaceutical technology as well as R&D strategy from early stages of drug development through to new drug application and launch. With the acquisition of Jitsubo Co, Ltd in April of 2021, SPERA PHARMA can now also offer Jitsubo’s unique liquid phase peptide manufacturing technology, Molecular Hiving™, to its clients. SPERA’s CMC capabilities therapeutic area agnostic; however, most the company’s current clients are focused on oncology, immuno-oncology, CNS, immunology, and rare diseases. The company believes that their expertise in these areas enables them to deliver molecules more rapidly to their partners. SPERA intends to continually expand its efforts into other therapeutic areas with high unmet needs.
201 to 500 staff
Naris Cosmetics
Naris Cosmetics is a pharmaceuticals company based out of 34 Hopper Ave, Nutley, New Jersey, United States.
11 to 50 staff
Nihon Medi-Physics Co., Ltd
We contribute to solving difficult healthcare issues using molecular imaging technologies Nihon Medi-Physics has been contributing to society through useful healthcare products that utilize the unique features of radioisotopes. Based on our mission of ensuring a stable supply of high quality products as well as continuing to develop new products and technologies that meet medical needs, our ultimate goal is to be a company that is always trusted by our stakeholders. Advances in medical technologies have acted as a constant driver for changes in the healthcare environment. Our core business consists of the nuclear medicine scan known as SPECT and PET, which are molecular imaging procedures. Molecular imaging captures and visualizes slight changes that occur inside the body, thus demonstrating extensive potential for challenging medical issues. In particular, a PET scan is an essential tool for the latest cancer treatments. Nihon Medi-Physics obtained approval for the first radiopharmaceutical agent for the PET procedure in Japan in 2005, and ever since, we have been distributing this agent to medical institutions nationwide. In 2015, we opened a tenth PET agent manufacturing site to further strengthen the product distribution network to ensure a stable supply. Moreover, by leveraging the experience and know-how cultivated in the manufacturing and distribution of radiopharmaceuticals, we recently diversified into contract businesses to promote the PET imaging procedure as a drug development tool in both non-clinical and clinical stages. Also, as an R&D oriented pharmaceutical company, we are actively engaged in the development of new products and expansion of our product line. Fully utilizing our strengths with all our effort, we will continue to explore more possibilities to help as many patients as possible achieve better outcomes, for themselves and their loved ones.
501 to 1000 staff
Orphanpacific Inc
OrphanPacific, Inc. is a Japanese pharmaceutical company specializing in the development, manufacturing and distribution of Orphan Drugs. Our mission is to "bring smiles and happiness to patients with rare diseases and their families," and we are committed to tackling the various challenges surrounding rare diseases. By collaborating with pharmaceutical companies and research institutions both domestically and internationally, we strive to deliver new treatments to patients in Japan while also ensuring the stable supply of existing orphan drugs. Our product portfolio focuses on treatments for rare diseases and includes a diverse range of pharmaceuticals aimed at improving patients' quality of life. Our efforts extend to particularly challenging areas within rare diseases, such as ultra-orphan drugs and treatments for pediatric patients. This commitment is rooted in our corporate philosophy of "Leave No One Behind." As a small company with around 50 employees, we each leverage our expertise while expanding our roles and embracing new challenges. Dedicated to pursuing an ethical and sustainable business model, we emphasize our social responsibility. Through collaboration with healthcare professionals and patient organizations, we engage in awareness and information-sharing activities related to rare diseases, ensuring that our initiatives reflect the voices of patients. OrphanPacific continues to create new value at the forefront of rare disease treatment for the benefit of patients.
51 to 200 staff
Sanwa Kagaku Kenkyusho Co., Ltd
SKK was founded in 1953 as a subsidiary of Suzuken. SKK researches, develops, manufactures, and markets pharmaceuticals.
501 to 1000 staff
A2 Healthcare Corporation
Unlock the potential of global drug development with A2 Healthcare. Expedite your entry into the dynamic healthcare markets of Japan and Taiwan. – Secure New Drug Application (NDA) approval with A2 Healthcare's unmatched regulatory expertise – Strategic clinical study partner for excellence at every stage of clinical development As a leading clinical Contract Research Organization (CRO) with a team of 1,300 experts, our mission is to catalyze your unparalleled success within Japan and Taiwan's pharmaceutical and biotech sectors. To learn more, contact our Boston office today.
1001 to 5000 staff
Anges Mg, Inc
AnGes MG, Inc. is a biopharmaceutical company founded December based on an innovative discovery by researchers of Osaka University. We specialize in R&D and practical application of genetic medicine. At present, we are engaged in developing two new medicines: the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and NFkB decoy which controls various inflammations. We are also making every effort to develop the HVJ Envelope Vector(a new delivery technology for medicines) through our subsidiary, GenomIdea Inc. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL). We are as determined as ever to continue our efforts to satisfy the expectations of patients and families who await new drugs, as well as those of shareholders, investors, and society as a whole.
51 to 200 staff
Bushu Pharmaceuticals Ltd
Japan’s premier contract manufacturing organization. Offering the best in Pharmaceutical Manufacturing & Supply Chain solutions. We produce high-quality pharmaceutical and medical devices with advanced quality control and supply chain management support. With more than 22 years as a contract manufacturer, we are constantly focused on how to improve our ability to deliver quality products to our customers. Based on our successes, we are now proud to have nearly 70 commercial partnerships.
1001 to 5000 staff
